RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 09, 2008, titled "Ranbaxy and DBT Collaborate in the Area of NDDR; To Focus On Tuberculosis Disease Segment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_09042008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 08, 2008, titled "Ranbaxy becomes first foreign generic company to develop a generic product independently outside Japan and receive authorisation from MHLW - Japan; Receives first independent product authorisation for Amlodipine Tablets in Japan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_08042008.zip target=NEW> Fo

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 03, 2008, titled "Ranbaxy Launches Worlds First Bio-Generic Recombinant Injectible for the Treatment of Osteoporosis in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/RanbaxyLab_PR_03042008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 28, 2008, titled "Ranbaxy Annual Audited Results for Year 2007; Net Profit up 67% at USD 190 Mn (Rs 7,866 MN); Global Sales record Robust Growth of 21% at USD 1619 MN (Rs 66,927 MN); Board approves Final dividend of 120% taking total dividend for 2007 to 170%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_28032008.zip targ

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 18, 2008, titled "Ranbaxy to introduce INERSAN brand in India and Nepal. Signs exclusive in-licensing agreement with CD Pharma, the Indian affiliate of US- based VSL Pharmaceuticals. First of its kind break- through drug in the Dental segment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_pr_18032008.zip target=NEW> For mo

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 19, 2008, titled "Ranbaxy Board Clears Scheme of De-merger of New Drug Discovery Research Unit; Shareholders to receive one equity share of Re.1 each in RLSRL for every four equity shares of Rs.5, held in Ranbaxy". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19022008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 07, 2008, titled "Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules in USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_07022008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 06, 2008, titled "Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension in USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_06022008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 21, 2008, titled "Ranbaxy Announces Settlement of Possible Imitrex(R) Litigation with Glaxosmithkline". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_21012008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 17, 2008, titled "Net Profit for the year increases 53% to Rs 7,901 MN; Global Sales at USD 1607 MN, UP 20%; Global Sales for Q4 at USD 451 MN; + 19% - Net Profit at Rs 1,878 MN". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_17012008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 11, 2008, titled "Ranbaxy enters the Chyawanprash Market; Launches its Sugar Free Brand - Chyawan Active". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_11012008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 31, 2007, titled "Ranbaxy receives final approval to manufacture and market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_31122007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 06, 2007, titled "Ranbaxy receives approval to manufacture and market ARV Combination for Children in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_06122007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 21, 2007, titled "Ranbaxy Launches RAN(R)-Tamsulosin Hydrochloride Capsules in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_21112007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 08, 2007, titled "Ranbaxy and Astellas/Boehringer Ingelheim enter into an Agreement to resolve Tamsulosin U.S. Patent Litigation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_08112007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 30, 2007, titled "Ranbaxy Granted Favorable Decision By Federal Patent court In Germany - On Pfizer's 281 Atorvastatin Patent". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/Ranbaxy_PR_30102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 29, 2007, titled "Ranbaxy Receives Tentative Approval From US FDA For Valsartan Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/Ranbaxy_PR_29102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 24, 2007, titled "Ranbaxy launches Osonase Nasal Spray in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_24102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 22, 2007, titled "Ranbaxy receives approval to market Ran (R)-Lisinopril in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_221012007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 18, 2007, titled "Ranbaxy's Q3 PAT increases 48%, Stands at Rs.2,074 MN". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_18102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 04, 2007, titled "Ranbaxy First To Gain Approval To Manufacture and Market Clarithromycin For Oral Suspension, USP". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_04102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 03, 2007, titled "Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology to enhance equity stake in Zenotech Laboratories to 45%". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_03102007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 24, 2007, titled "Ranbaxy forays into Liver Cancer Market - Enters into an In-licensing agreement with Sirtex, Australia Ranbaxy to market in India, Bangladesh, Sri Lanka and Nepal". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_24092007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 13, 2007, titled "Canadian Federal Court favours Ranbaxy - Dismisses Pfizer's application on Atorvastatin Patent CA 2,220,455". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_13092007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 10, 2007, titled "Ranbaxy receives WHO pre-qualification for three additional ARVs-Two products introduced for the first time on the WHO list". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_10092007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 22, 2007, titled "Ranbaxy launches Urology Drug Roliflo* OD based on Multiparticulate NDDS Technology". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_22082007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 20, 2007 titled "Ranbaxy receives US FDA approval to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_200807.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 30, 2007, titled "Ranbaxy Commercialises its First Authorised Generic, ISOPTIN(R)SR, in the US". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_300707.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 26, 2007, titled "Ranbaxy and Gsk Enter into an agreement to settle valacyclovir US Patent Litigation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_260707.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 19, 2007, titled "Ranbaxy Q2 Global Sales at USD 395 MN, up 25% (Rs.1,624 CR)". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19072007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 10, 2007, titled "Ranbaxy Receives Final US FDA Approval To Manufacture And Market Amlodipine Besylate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_10072007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 25, 2007, titled "Ranbaxy launches Pravastatin Sodium 80 MG Tablets in USA; Ranbaxy to benefit from 180 day exclusivity". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_250607.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 22, 2007, titled "Ranbaxy receives tentative approval from US FDA for Tamsulosin Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_22062007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 20, 2007, titled "Ranbaxy receives tentative approval from US FDA to manufacture and market Amlodipine Besylate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_20062007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 29, 2007, titled "Ranbaxy Wins on all Four Atorvastatin Patents in Norway". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_300507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 28, 2007, titled "Ranbaxy Expands Its Presence in the U.S. Dermatology Market Through the Acquisition of 13 Brands from Bristol Myers Squibb". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR280507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 21, 2007, titled "Ranbaxy Receives Approval to Market Ran (R) - Pravastatin in Canada". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RanbaxyPR210507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 18, 2007, titled "Ranbaxy receives Tentative FDA approval for Fexofenadine Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RanbaxyPR180507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 08, 2007, titled "Pharmaceutical Major Ranbaxy Laboratories Extends Roots in South Africa with Finalisation of BE-TABS Acquisition". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR070507.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 27, 2007, titled "Ranbaxy Q1 2007 Net Profit rises 79% to Rs 129 Crores; Operating Profit before Tax at Rs 160 Crores, up 100%; Global Sales at Rs 1,564 Crores record growth of 23%; Management ups guidance for full year to 20% sales growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_270407.zip target=NEW> For more detai

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 26, 2007, titled "Ranbaxy Receives Final US FDA Approval to Manufacture and Market Zolpidem Tablets in USA". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR260407.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 25, 2007, titled "Ranbaxy receives US FDA approval to manufacture and market Pravastatin Sodium Tablets in USA - Ranbaxy granted 180 days exclusivity for 80MG Dosage". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/rANBAXY_pr_25042007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 12, 2007, titled "Ranbaxy Receives Approval to Market Cefprozil Tablets and Cefprozil Powder for Oral Suspension in Canada". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated April 03, 2007, titled "Terapia Ranbaxy receives GMP Certificate renewal from National Agency of Medicine for Bucharest site". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_03042007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 02, 2007, titled "Ranbaxy's Drug Discovery Team achieves significant Milestone in GSK Research Collaboration; Development Candidate approved for Respiratory Inflammation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_020407.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 28, 2007, "Ranbaxy launches Osovair for the treatment of Asthma - World's first novel product of its kind introduced in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RanbaxyPR_28032007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated March 16, 2007, titled "Ranbaxy receives tentative USFDA approval to manufacture and market Zolpidem Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_160307.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated March 11, 2007, titled "Dr. Himadri Sen to join Ranbaxy as President R&D". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_12032007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd regarding a press release dated March 07, 2007, titled "Terapia Ranbaxy gets Market Authorisations for 20 new products". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_070307.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated March 01, 2007, titled "PPD Licenses Statin from Ranbaxy Laboratories". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_010307.zip target=NEW> For more details click here.</a>